廣告
香港股市 已收市

  • 恒指

    22,736.87
    +623.36 (+2.82%)
     

  • 國指

    8,156.50
    +242.34 (+3.06%)
     

  • 上證綜指

    3,336.50
    +248.97 (+8.06%)
     

  • 滬深300

    4,017.85
    +314.17 (+8.48%)
     

  • 美元

    7.7662
    +0.0016 (+0.02%)
     

  • 人民幣

    0.9031
    -0.0003 (-0.03%)
     

  • 道指

    42,352.75
    +341.16 (+0.81%)
     

  • 標普 500

    5,751.07
    +51.13 (+0.90%)
     

  • 納指

    18,137.85
    +219.38 (+1.22%)
     

  • 日圓

    0.0520
    -0.0006 (-1.22%)
     

  • 歐元

    8.5249
    -0.0402 (-0.47%)
     

  • 英鎊

    10.1870
    0.0000 (0.00%)
     

  • 紐約期油

    74.45
    +0.74 (+1.00%)
     

  • 金價

    2,673.20
    -6.00 (-0.22%)
     

  • Bitcoin

    62,023.07
    -199.45 (-0.32%)
     

  • XRP USD

    0.53
    -0.00 (-0.62%)
     

Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term

Zacks Equity Research
·2 分鐘文章

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.

Why This 1 Growth Stock Should Be On Your Watchlist

Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Becton Dickinson (BDX)

Based in Franklin Lakes, NJ, Becton, Dickinson and Company, commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.

BDX is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 7.3% year-over-year for the current fiscal year, with sales growth of 4%.

Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.06 to $13.10 per share. BDX also boasts an average earnings surprise of 6.2%.

On a historic basis, Becton Dickinson has generated cash flow growth of 3.7%, and is expected to report cash flow expansion of 5.1% this year.

Investors should take the time to consider BDX for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Becton, Dickinson and Company (BDX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research